{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:24:52Z","timestamp":1791379492150,"version":"4.3.2"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100001502","name":"Blue Cross Blue Shield of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001502","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Blue Care Network"},{"name":"BCBSM"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunocompromised patients are often excluded from pneumonia trials, guidelines, and stewardship interventions. The objective of this study was to evaluate whether empiric broad-spectrum antibiotic (BSA) treatment impacts mortality and other clinical outcomes in moderately immunocompromised patients without risk factors for multidrug-resistant organisms (MDROs) hospitalized with community-acquired pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a target trial emulation including moderately immunocompromised (asplenia, hematologic malignancies, solid organ malignancy receiving chemotherapy, kidney transplant &amp;gt;1 year prior, congenital\/acquired immunodeficiency, and receiving immunosuppressive medications) patients with pneumonia without risk factors for MDROs at 69 hospitals in the Michigan Hospital Medicine Safety Consortium. This study compared the receipt of empiric BSAs against antibiotics targeting typical respiratory pathogens on hospital day 1 or 2. The primary outcome was mortality. Secondary outcomes included length of stay, transfer to the intensive care unit (ICU) and 30-day readmission, emergency department visit, Clostridioides difficile infection, and antibiotic-associated adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 2706 moderately immunocompromised patients with pneumonia, 59% (n = 1596) received empiric BSAs. Methicillin-resistant Staphylococcus aureus and resistant gram-negative bacteria were rare (94\/2706 [3.5%]). After adjustment, empiric BSA treatment was not associated with mortality, but was associated with readmission (adjusted hazard ratio [aHR], 1.32 [95% confidence interval {CI], 1.05\u20131.66]), transfer to ICU (aHR, 2.65 [95% CI, 1.32\u20135.30]), and longer hospitalization (adjusted rate ratio, 1.14 [95% CI, 1.10\u20131.19]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Immunocompromised patients hospitalized with pneumonia often receive empiric BSAs despite low rates of MDROs. Empiric BSA use was not associated with mortality, but was associated with harm, including 30-day readmission, transfer to ICU, and longer duration of hospitalization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf344","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:58:58Z","timestamp":1751443138000},"page":"648-657","source":"Crossref","is-referenced-by-count":9,"title":["Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5670-5101","authenticated-orcid":false,"given":"Louis","family":"Saravolatz","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejal N","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-7842","authenticated-orcid":false,"given":"Valerie M","family":"Vaughn","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Internal Medicine, University of Utah School of Medicine , Salt Lake City, Utah ,","place":["USA"]},{"name":"Division of Health System Innovation and Research, Department of Population Health Science, University of Utah School of Medicine , Salt Lake City, Utah ,","place":["USA"]},{"name":"Division of Hospital Medicine, Department of Internal Medicine, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ratz","sequence":"additional","affiliation":[{"name":"Center for Clinical Management Research, Veterans Affairs Ann Arbor Health System , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2545-0636","authenticated-orcid":false,"given":"Jennifer K","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Internal Medicine, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Internal Medicine, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Medicine Service, Veterans Affairs Ann Arbor Healthcare System , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Internal Medicine, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawny","family":"Czilok","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Internal Medicine, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Weinmann","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Henry Ford Health , Detroit, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-7149","authenticated-orcid":false,"given":"David","family":"Paje","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Internal Medicine, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Medicine Service, Veterans Affairs Ann Arbor Healthcare System , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag N","family":"Malani","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Trinity Health Michigan , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Burdick","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Corewell Health , Grand Rapids, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7062-9619","authenticated-orcid":false,"given":"Danielle","family":"Osterholzer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Hurley Medical Center , Flint, Michigan ,","place":["USA"]},{"name":"Department of Internal Medicine, Michigan State University College of Human Medicine , East Lansing, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A","family":"Flanders","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Internal Medicine, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay A","family":"Petty","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"2026043013114612800_ciaf344-B1","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026043013114612800_ciaf344-B2","first-page":"194","article-title":"Vital signs: improving antibiotic use among hospitalized patients","volume":"63","author":"Fridkin","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026043013114612800_ciaf344-B3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1469-0691.2012.03765.x","article-title":"Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome","volume":"19","author":"Sousa","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2026043013114612800_ciaf344-B4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.rmed.2008.08.006","article-title":"Epidemiology of community-acquired pneumonia in older adults: a population-based study","volume":"103","author":"Vila-Corcoles","year":"2009","journal-title":"Respir Med"},{"key":"2026043013114612800_ciaf344-B5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamainternmed.2016.3633","article-title":"Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial","volume":"176","author":"Uranga","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2026043013114612800_ciaf344-B6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/cid\/ciab950","article-title":"A statewide collaborative quality initiative to improve antibiotic duration outcomes in patients hospitalized with uncomplicated community-acquired pneumonia","volume":"75","author":"Vaughn","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026043013114612800_ciaf344-B7","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1001\/archinte.164.16.1807","article-title":"Culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system","volume":"164","author":"Garcia-Vazquez","year":"2004","journal-title":"Arch Intern Med"},{"key":"2026043013114612800_ciaf344-B8","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1378\/chest.121.5.1486","article-title":"Applying sputum as a diagnostic tool in pneumonia. Limited yield, minimal impact on treatment decisions","volume":"121","author":"Ewig","year":"2002","journal-title":"Chest"},{"key":"2026043013114612800_ciaf344-B9","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026043013114612800_ciaf344-B10","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/cid\/ciy723","article-title":"Prevalence and etiology of community-acquired pneumonia in immunocompromised patients","volume":"68","author":"Di Pasquale","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026043013114612800_ciaf344-B11","doi-asserted-by":"crossref","first-page":"1900057","DOI":"10.1183\/13993003.00057-2019","article-title":"Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study","volume":"54","author":"Webb","year":"2019","journal-title":"Eur Respir J"},{"key":"2026043013114612800_ciaf344-B12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamainternmed.2019.7495","article-title":"Empirical anti-MRSA vs standard antibiotics therapy and risk of 30-day mortality in patients hospitalized for pneumonia","volume":"180","author":"Jones","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2026043013114612800_ciaf344-B13","doi-asserted-by":"crossref","first-page":"ofab373","DOI":"10.1093\/ofid\/ofab373","article-title":"Predictors of readmission following discharge of patients with gram-negative bacteremia: a retrospective cohort study","volume":"8","author":"Porat","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026043013114612800_ciaf344-B14","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/cid\/ciac104","article-title":"Antibiotic stewardship strategies and their association with antibiotic overuse after hospital discharge: an analysis of the Reducing Overuse of Antibiotics at Discharge (ROAD) home framework","volume":"75","author":"Vaughn","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026043013114612800_ciaf344-B15","doi-asserted-by":"crossref","first-page":"ofaa007","DOI":"10.1093\/ofid\/ofaa007","article-title":"A deeper dive into antibiotic stewardship needs: a multihospital survey","volume":"7","author":"Vaughn","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026043013114612800_ciaf344-B16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/cid\/ciab950","article-title":"A statewide collaborative quality initiative to improve antibiotic duration and outcomes in patients hospitalized with uncomplicated community-acquired pneumonia","volume":"75","author":"Vaughn","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026043013114612800_ciaf344-B17","volume-title":"National Healthcare Safety Network (NHSN) Patient Safety Component Manual. Chapter 4: Bloodstream infection event (central line\u2013associated bloodstream infection and non-central line associated bloodstream infection)","author":"Centers for Disease Control and Prevention (CDC)","year":"2024"},{"key":"2026043013114612800_ciaf344-B18","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1017\/ice.2021.341","article-title":"Risk factors and outcomes associated with community-onset and hospital-acquired coinfection in patients hospitalized for coronavirus disease 2019 (COVID-19): a multihospital cohort study","volume":"43","author":"Petty","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026043013114612800_ciaf344-B19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"2026043013114612800_ciaf344-B20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"2026043013114612800_ciaf344-B21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2026043013114612800_ciaf344-B22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026043013114612800_ciaf344-B23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1513\/AnnalsATS.201407-305OC","article-title":"Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia","volume":"12","author":"Prina","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026043013114612800_ciaf344-B24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/cid\/cix411","article-title":"Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms","volume":"65","author":"Barrasa-Villar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026043013114612800_ciaf344-B25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/cid\/ciw300","article-title":"Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes","volume":"63","author":"Self","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026043013114612800_ciaf344-B26","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.chest.2020.05.598","article-title":"Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies","volume":"158","author":"Ramirez","year":"2020","journal-title":"Chest"},{"key":"2026043013114612800_ciaf344-B27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cir840","article-title":"Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia","volume":"54","author":"Aliberti","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026043013114612800_ciaf344-B28","doi-asserted-by":"crossref","first-page":"e202899","DOI":"10.1001\/jamanetworkopen.2020.2899","article-title":"Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum antibiotic use","volume":"3","author":"Rhee","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026043013114612800_ciaf344-B29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000513742","article-title":"Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: a comprehensive review","volume":"52","author":"Blair","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026043013114612800_ciaf344-B30","doi-asserted-by":"crossref","first-page":"e2211331","DOI":"10.1001\/jamanetworkopen.2022.11331","article-title":"Pharmacist-drive transitions of care practice model for prescribing oral antimicrobials at hospital discharge","volume":"5","author":"Mercuro","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026043013114612800_ciaf344-B31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijid.2020.11.172","article-title":"The impact of a stewardship program on antibiotic administration in community-acquired pneumonia: results from an observational before-after study","volume":"103","author":"Fally","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2026043013114612800_ciaf344-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2011.03602.x","article-title":"Guidelines for the management of adult lower respiratory tract infections\u2014summary","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2026043013114612800_ciaf344-B33","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/cid\/ciz1049","article-title":"Blood cultures versus respiratory cultures: 2 different views of pneumonia","volume":"71","author":"Haessler","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026043013114612800_ciaf344-B34","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf344\/63648647\/ciaf344.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/648\/63648647\/ciaf344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/648\/63648647\/ciaf344.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:11:55Z","timestamp":1777569115000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/4\/648\/8182678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7,2]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf344","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2025,7,2]]}}}